Precirix

Burgemeester Etienne Demunterlaan 3

1090 Brussel (Jette)

BE

Precirix

Foundation date

14/10/2014

Sector

#Biotechnology - Therapeutics

Therapeutic areas

Precirix is a private, clinical-stage biopharmaceutical company dedicated to extending and improving the lives of cancer patients by designing and developing novel radiopharmaceuticals, using camelid-derived single-domain antibodies (sdAb) labeled with radioisotopes.

The company’s lead product, CAM-H2, is being evaluated in a Phase I/II trial targeting metastatic HER2-positive cancer. Patients with tumors that overexpress HER2 can benefit from effective targeted treatments today yet have a poor prognosis when the cancer spreads. CAM-H2 aims to effectively irradiate cancer lesions while sparing healthy tissue, based on its unique technology platform that leverages the favorable tissue distribution of sdAbs.

The company’s technology platform also allows for a theranostic approach, using the same molecule for patient selection (imaging) and therapy. In addition to CAM-H2, the company has two product candidates in preclinical stage and is further broadening its platform through research on isotopes, linker technology and combination therapies.

Upcoming events

Latest news

  • HERAN Partners co-leads the GBP 6,5m financing round of Hypervision Surgical to support the further development and commercial roll-out of their Hyperspectral Imaging platform

    Tuesday June 6th 2023

  • ANeuroTech receives IND approval from the FDA for pivotal Phase IIIB trial of adjunctive anti-depression drug, ANT-01

    Monday June 5th 2023

  • Biotalys continues to demonstrate strength of first biocontrol in latest global field trials

    Friday June 2nd 2023

Jobs by Precirix